Solesence, Inc. Common Stock (SLSN) - Net Assets
Based on the latest financial reports, Solesence, Inc. Common Stock (SLSN) has net assets worth $29.66 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($47.79 Million) and total liabilities ($18.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Solesence, Inc. Common Stock to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.66 Million |
| % of Total Assets | 62.05% |
| Annual Growth Rate | 23.97% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 308.89 |
Solesence, Inc. Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how Solesence, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See SLSN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Solesence, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of Solesence, Inc. Common Stock from 2021 to 2025. For live valuation and market cap data, see SLSN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $17.63 Million | +17.98% |
| 2024-12-31 | $14.95 Million | +685.80% |
| 2023-12-31 | $1.90 Million | -66.33% |
| 2022-12-31 | $5.65 Million | -24.33% |
| 2021-12-31 | $7.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solesence, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 119100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $706.00K | 4.00% |
| Other Components | $115.57 Million | 655.36% |
| Total Equity | $17.63 Million | 100.00% |
Solesence, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Solesence, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aroot Co. Ltd
KQ:096690
|
$90.42 Million |
|
Bridgemarq Real Estate Services Inc
TO:BRE
|
$90.42 Million |
|
LINMON MEDIA LTD -000025
F:8MN
|
$90.44 Million |
|
BCP Investment Corp.
NASDAQ:BCIC
|
$90.48 Million |
|
Kyongbo Pharmaceutical Co Ltd
KO:214390
|
$90.40 Million |
|
OncoCyte Corp
NASDAQ:OCX
|
$90.37 Million |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
$90.36 Million |
|
AptaBio Therapeutics Inc
KQ:293780
|
$90.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solesence, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,946,000 to 17,634,000, a change of 2,688,000 (18.0%).
- Net income of 1,790,000 contributed positively to equity growth.
- Other factors increased equity by 898,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.79 Million | +10.15% |
| Other Changes | $898.00K | +5.09% |
| Total Change | $- | 17.98% |
Book Value vs Market Value Analysis
This analysis compares Solesence, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.07x to 5.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.16 | $1.28 | x |
| 2022-12-31 | $0.12 | $1.28 | x |
| 2023-12-31 | $0.04 | $1.28 | x |
| 2024-12-31 | $0.23 | $1.28 | x |
| 2025-12-31 | $0.24 | $1.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solesence, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.15%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.88%
- • Asset Turnover: 1.24x
- • Equity Multiplier: 2.84x
- Recent ROE (10.15%) is above the historical average (-41.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 31.08% | 7.87% | 1.04x | 3.80x | $1.57 Million |
| 2022 | -46.43% | -7.03% | 1.11x | 5.94x | $-3.19 Million |
| 2023 | -230.81% | -11.77% | 1.13x | 17.29x | $-4.58 Million |
| 2024 | 28.34% | 8.09% | 1.05x | 3.35x | $2.74 Million |
| 2025 | 10.15% | 2.88% | 1.24x | 2.84x | $26.60K |
Industry Comparison
This section compares Solesence, Inc. Common Stock's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $681,211,031
- Average return on equity (ROE) among peers: -402.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solesence, Inc. Common Stock (SLSN) | $29.66 Million | 31.08% | 0.61x | $90.41 Million |
| Acme United Corporation (ACU) | $20.60 Million | 6.31% | 1.00x | $158.51 Million |
| Bruush Oral Care Inc. (BRSHF) | $163.14K | -5449.60% | 11.70x | $10.10K |
| Park Ha Biological Technology Co., Ltd. (BYAH) | $150.28K | 127.30% | 15.76x | $12.69 Million |
| Church & Dwight Company Inc (CHD) | $2.06 Billion | 16.97% | 0.99x | $21.50 Billion |
| Colgate-Palmolive Company (CL) | $197.00 Million | 1218.27% | 60.73x | $70.06 Billion |
| The Clorox Company (CLX) | $932.80 Million | 23.81% | 1.34x | $10.75 Billion |
| Coty Inc (COTY) | $1.62 Billion | 10.40% | 3.00x | $1.67 Billion |
| Carmell Therapeutics Corporation (CTCX) | $-37.79 Million | 0.00% | 0.00x | $4.61 Million |
| Big Tree Cloud Holdings Limited Ordinary Shares (DSY) | $57.19 Million | 0.22% | 0.04x | $5.78 Million |
| Estee Lauder Companies Inc (EL) | $1.97 Billion | 24.34% | 1.71x | $20.39 Billion |
About Solesence, Inc. Common Stock
Solesence, Inc., a science-driven company, provides engineered materials, formulation development, and commercial manufacturing services in the United States. The company engages in the manufacture and supply of surface engineered zinc oxide and titanium dioxide ingredients. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingre… Read more